Cannabis smoking constitutes a substantial hazard to the lung (Sorry)

Cannabis (or marijuana) is not only the most widely used illegal drug in the western world but, after tobacco, also the most commonly smoked substance. In the UK almost 50% of young adults have tried to smoke cannabis at some time. Among people aged 16–30 years of age there is a substantial number of frequent users, in some populations in the range of about 5%. The active substance responsible for the psychostimulating effect of cannabis is delta9-tetrahydrocannabinol (THC). However, as with tobacco smoke, cannabis smoke consists of a large mixture of compounds including polycyclic aromatic hydrocarbons, carbon monoxide, cyanide, benzene and many others.  

Cannabis is prepared from the hemp plant which—especially in the 19th and the beginning of the 20th century—was grown for industrial purposes in order to produce fibers, but it has gradually been replaced by other coarse-fiber plants. Archaeological findings show that cannabis was used in many ancient cultures in spiritual and religious contexts as a psychostimulating and trance-inducing drug. Later, in the 19th century, it was promoted for its medical properties including pain-relieving, antiemetic and anticonvulsant effects. Yet, after the invention of aspirin and other more effective drugs, the use of cannabis as a popular medical drug declined.

The so-called recreational use of cannabis became more widespread during the golden period of jazz in the 1920s and 1930s and later became a part of the youth culture in the 1960s. Although cannabis can be prepared for consumption in several forms (beverages, cakes, oils), the most usual intake is by inhalation through the lungs. Cannabis can be smoked in cigarettes (joints), pipes or in special devices such as bong or chillum. Irrespective of the device, the technique of smoking cannabis differs from smoking regular tobacco with larger puffs, deeper inhalation and greater breath holding time, sometimes accompanied by valsalva maneuvers to achieve a higher systemic absorption of THC. In fact, this smoking technique (rather than cannabis itself) has been proposed as the mechanism responsible for cases of spontaneous pneumothorax and bullous lung disease reported in young cannabis smokers. Most importantly, however, this smoking technique results in a far greater deposition of toxic substances in the lung than with regular tobacco smoking.  

The number of studies on the pulmonary effects of cannabis is quite limited. In particular, in contrast to the worldwide research on tobacco, relatively few research groups have conducted relevant studies on the pulmonary effects of cannabis. Most of our knowledge comes from the University of Southern California where Tashkin et al have, since the early 1970s, performed several experimental, clinical and epidemiological studies. However, there is now an increasing focus on the possible harmful effects of cannabis on the lung. A recent systematic review of the literature identified 34 relevant publications evaluating either short-term or long-term effects of cannabis smoking on pulmonary function and respiratory symptoms. This review confirms that, although cannabis smoking results in an acute bronchodilation, it exerts very potent inflammatory effects on the airways which, in the longer term, result in a very high prevalence of cough, sputum and wheeze. These clinical symptoms are paralleled by bronchoscopic findings showing mucosal swelling and erythema, increased airway secretions, goblet cell hyperplasia, loss of ciliated epithelium, squamous metaplasia and an increased number of alveolar macrophages with impaired microbiocidal activity. The latter finding is consistent with case reports of opportunistic pulmonary infections in cannabis smokers.

With regard to the risk of developing respiratory cancer, the evidence is more controversial. Yet, as cannabis smoke contains similar carcinogens to tobacco smoke and the smoking technique results in an even higher concentration and the deposition in the airways of inhaled particles, it is likely that cannabis smoking could cause airway malignancies. However, a large epidemiological study failed to show an increased risk in cannabis smokers, but this study has been criticized by others because the follow-up period was too short.

The findings regarding the long-term effects of cannabis smoking on pulmonary function are also conflicting and previous reviews have concluded that data on an association between cannabis smoking and reduced pulmonary function are inconclusive. In this issue of Thorax Aldington et al present new data on this important problem. They compared lung function and high-resolution CT (HRCT) scans of 75 cannabis (only) smokers, 91 cannabis and tobacco smokers and 92 tobacco smokers with 81 non-smokers. They found a dose-response relationship between cannabis consumption and the degree of airways obstruction and hyperinflation. They estimated that one cannabis joint was equivalent to 2.5 cigarettes for the effect on forced expiratory volume in 1 s/forced vital capacity and to 6 cigarettes for the effect on specific airways conductance. In contrast, there was no association between cannabis use and the prevalence of HRCT-defined emphysema. This study supports the view that cannabis affects airway function and causes obstruction. It is likely that the present results differ from the previous negative studies due to the inclusion of subjects with a relatively high cumulated cannabis consumption (substantial number of joint-years) and because the cannabis cigarettes of today contain more than 10 times as much THC than cigarettes from the 1960s, as has been put forward by the British Lung Foundation (BLF). The BLF also points out that there is a need for further research focusing on the link between cannabis and chronic obstructive pulmonary disease. Yet, the study by Aldington et al also shows the difficulties in conducting such studies. In spite of the fact that the investigators invited a general population sample of 3500 individuals, there were only 19 eligible persons smoking cannabis. Another approach using specific advertising for cannabis smokers therefore had to be employed. However, as the authors point out, this approach is not without problems because many heavy cannabis consumers also smoke other substances, which makes it difficult to isolate the effects of cannabis.

In summary, although we know far less about the effect of cannabis on the lung than the effects of tobacco smoking, the study by Aldington et al confirms that cannabis smoking constitutes a substantial hazard to the lung.  

Peter Lange

Correspondence to:
Dr Peter Lange, Department of Cardiology and Respiratory Medicine, Hvidovre Hospital, Copenhagen, Denmark

 Cannabis Facts

·         Cannabis is the most widely consumed illegal drug in the UK

·         3-4 cannabis cigarettes a day are associated with the same evidence of acute and chronic bronchitis and the same degree of damage to the bronchial mucus membrane as 20 or more tobacco cigarettes a day

·         Cannabis tends to be smoked in a way which increases the puff volume by two-thirds and the depth of inhalation by one-third. There is an average fourfold longer breath-holding time with cannabis than with tobacco. This means that there is a greater respiratory burden of carbon monoxide and smoke particulates than when smoking a similar quantity of tobacco

·         The tar in a cannabis cigarette contains many of the same known carcinogens as tobacco smoke but the concentrations of these are up to 50% higher in the smoke of a cannabis cigarette

·         It also deposits four times as much tar on the respiratory tract as an unfiltered cigarette of the same weight. Smokers of cannabis and tobacco have shown a greater increase in cellular abnormalities indicating a cumulative effect of smoking both

·         In 2001/02, the most commonly used drug by young people was cannabis, which had been used by 33 per cent of young men and 21 per cent of young women in the previous year

·         44% of 16 to 29 year-olds have tried cannabis at some point in their lives

·         In 2001/02 there were 4.6 million 16 to 59-year-olds living in London. Among this population the British Crime Survey estimates prevalence of illicit drug use was 14 per cent for cannabis

Impact of cannabis smoking

·         It is difficult to ascertain whether or not the inhalation of cannabis smoke causes damage to the lungs and airways independently of the tobacco smoke or not. In general, the studies indicate that there is an increased negative health impact on those who do not smoke cannabis compared to those who do not smoke at all

·         When cannabis is smoked with tobacco, the effects are cumulative. However, what is not clear is whether it is the addition of cannabis or the tobacco which is more harmful or whether this is the result of the combined effect of equally harmful substances

·         Studies comparing the clinical effects of habitual cannabis smokers versus non-smokers demonstrate a significantly higher prevalence of chronic and acute respiratory symptoms such as chronic cough and sputum production, wheeze and acute bronchitis episodes

·         Cannabis smoking is likely to weaken the immune system. Infections of the lung are due to a combination of smoking-related damage to the cells lining the bronchial passage (the fine hair-like projection on these cells filter out inhaled micro-organisms) and impairment of the principal immune cells in the small air sacs caused by cannabis

·         The evidence concerning a possible link between cannabis smoking and COPD has not yet been conclusively established. A number of studies indicate a causal relationship between the two, whereas others contradict these findings

·         The THC in cannabis has been shown to have a bronchodilator effect. This has led to suggestions that THC may have therapeutic benefits in asthma. However, the noxious gases, chronic airway irritation or malignancy after long term use associated with smoking would seem to negate these benefits